HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorHansoh BioMedical R&D Company
About this trial
HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
This is a phase 1b, open-label, multi-center study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HS-20093 in patients with advanced gastric and gastroesophageal junction adenocarcinoma.
Eligibility criteria
Qualifiers
At least age of 18 years at screening, with no restrictions on gender.
Signed and dated Informed Consent Form.
Participants with pathologically or cytologically confirmed locally advanced unresectable or metastatic GC/GEJC, who have failed, or intolerant to standard therapies.
At least one extra measurable lesion according to RECIST 1.1.
Disqualifiers
Previous or current treatment with B7-H3 targeted therapy.
Previous or current treatment with topoisomerase I inhibitors.
Any cytotoxic chemotherapy, investigational agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093
Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093
Trial design
Treatments tested in this trial
- HS-20093 for injection
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov